Mixed
Dihydroberberine (dhBBR), a derivative of berberine, exhibits significantly improved in vivo efficacy, reduced adiposity, and improved insulin sensitivity compared to berberine at equivalent lower doses.
Dihydroberberine (dhBBR) is a derivative of berberine that is much better absorbed by the body. In rodent studies, dhBBR was significantly more effective at reducing fat and improving insulin sensitivity than standard berberine at the same dose. This suggests that for metabolic benefits, the form of berberine (bioavailability) is critical.
Strikingly, one derivative (dhBBR) displayed similar potency to BBR to stimulate both glucose uptake and AMPK... and hence its effects were examined in rodent models of insulin resistance.
Why this rating
Strong rodent data showing clear metabolic benefits; human data is not primary to this paper.
Source
Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I
Nigel Turner et al. · Diabetes · 2008
DOI 10.2337/db07-1552
More from this paper
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →